POS0198 COVID-19 OUTCOMES IN PATIENTS WITH DERMATOMYOSITIS: A REGISTRY-BASED COHORT ANALYSIS

Background Dermatomyositis (DM) patients have fewer risks of COVID-19 infection compared to the general population, however, certain subgroups with DM worse outcomes. Men. African Americans, those interstitial lung disease, exhibited higher severe COVID-19. DMARD and glucocorticoid use was associated frequent hospitalisations sepsis. Objectives Rheumatic diseases (RDs) like DM, are previously known be vulnerable towards various types infections due its aggressive activity mandating high dose immunosuppressive therapy. The severity in RDs is limited literature heterogeneous nature condition. Therefore, specific details on mortality essential navigate any precautions required treatment. Methods Retrospective data individuals population between January 2020 August retrieved from TriNetX database. A one-to-one matched positive control selected using propensity score (PS) matching. We assessed outcomes such as mortality, hospitalisation, ICU admission, COVID-19, mechanical ventilation (MV), acute kidney injury (AKI), venous thromboembolism (VTE), ischemic stroke, respiratory distress syndrome (ARDS), renal replacement therapy (RRT) Subgroup analyses included gender, race, ILD, cancer patients, disease-modifying rheumatic drugs (DMARDs) use, glucocorticoids (GC) (Figure 1). Figure 1. Overview study Results identified 5,574 (controls). had a lower risk comparison controls [RR 0.76], hospitalisation 0.8], AKI 0.83], sepsis 0.73]. Males Americans were more likely develop 1.35, 1.65], while odds for 1.62] VTE 1.54]. ILD group also experienced 1.64], 2.06] receiving DMARDs 1.46, 2.12], 3.25] analysis neoplasms amongst inadequate meaningful Conclusion protected aspects including hospitalization, mortality. American male DMARDS users, poor Disclosure Interests Latika Gupta: None declared, Haig Pakhchanian: Hiba Khan: Rahul Raiker: Maryam Abbasi: Charles DeYoung: Sinan Kardes Grant/research support from: SK has received congress travel, accommodation, participation fee (12th Anatolian Rheumatology Days) Abbvie, Sakir Ahmed Speakers bureau: SA honorarium speaker Pfizer, Chengappa Kavadichanda: Parikshit Sen: Rohit Aggarwal Consultant of: RA has/had consultancy relationship and/or research funding following companies-Bristol Myers-Squibb, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant., Roivant.